Table. Characteristics of the Study Patientsa.
| Characteristic | Active treatment (n = 11 840) | AS/WW (n = 8969) | P value |
|---|---|---|---|
| Race | |||
| American Indian or Alaska Native | 17 (0.1) | 14 (0.2) | .11 |
| Asian or Pacific Islander | 76 (0.6) | 72 (0.8) | |
| Black | 1125 (9.5) | 730 (8.1) | |
| White | 5029 (42.5) | 3322 (37.0) | |
| Otherb | 92 (0.8) | 77 (0.9) | |
| Missing | 5501 (46.5) | 4754 (53.0) | |
| Age decile, y | |||
| 40s | 508 (4.3) | 261 (2.9) | <.001 |
| 50s | 3190 (26.9) | 2189 (24.4) | |
| 60s | 5506 (46.5) | 4263 (47.5) | |
| 70s | 2373 (20.0) | 2059 (23.0) | |
| 80s | 256 (2.2) | 193 (2.2) | |
| Missing | 7 (0.1) | 4 (0.0) | |
| Year of diagnosis | |||
| 2014 | 1406 (11.9) | 506 (5.6) | <.001 |
| 2015 | 1466 (12.4) | 692 (7.7) | |
| 2016 | 1738 (14.7) | 812 (9.1) | |
| 2017 | 1756 (14.8) | 967 (10.8) | |
| 2018 | 1677 (14.2) | 1250 (13.9) | |
| 2019 | 1650 (13.9) | 1747 (19.5) | |
| 2020 | 1383 (11.7) | 1870 (20.8) | |
| 2021 | 764 (6.5) | 1125 (12.5) | |
| PSA level at diagnosis, ng/mL | |||
| Mean (SD) | 5.31 (1.97) | 5.31 (1.89) | .96 |
| Median (range) | 5.10 (0.60-10.00) | 5.09 (1.00-10.00) | |
| T stage | |||
| T1 | 3506 (29.6) | 2354 (26.2) | <.001 |
| T2 | 984 (8.3) | 490 (5.5) | |
| Missing | 7350 (62.1) | 6125 (68.3) |
Abbreviations: AS/WW, active surveillance or watchful waiting; PSA, prostate-specific antigen.
SI conversion factors: To convert PSA to micrograms per liter, multiply by 1.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
Other race includes any identified race in the electronic health record that did not match 1 of the US Census categories, including multiracial.